vyd2311
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Aug 28, 2024 (NCT06523153)
Timeline
Indications
Studied for
Mechanism of action
- SARS-CoV-2INHIBITOR
SARS-CoV-2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07298434 | Phase 3 | Jan 31, 2026 | Invivyd, Inc. |
| NCT06523153 | Phase 1 | Aug 28, 2024 | Invivyd, Inc., Novotech |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Invivyd, Inc. | For profit | 2 | 2 | 2 | 2024 |
| Novotech | For profit | 1 | 0 | 1 | 2024 |
2 organizations
Page 1 / 1